Your browser doesn't support javascript.
loading
Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy.
Li, Heng; Zhang, Yucong; Li, Dong; Ma, Xin; Xu, Kai; Ding, Beichen; Li, Hongzhao; Wang, Zhize; Ouyang, Wei; Long, Gongwei; Zeng, Jin; Liu, Haoran; Yan, Libin; Zhang, Yangjun; Liu, Zheng; Guan, Wei; Hu, Zhiquan; Liu, Cong; Wan, Jie; Wang, Guoping; Pu, Xiaoyong; Zhang, Minghui; Guo, Linlang; An, Ruihua; Qi, Jiping; Guo, Aitao; Ye, Zhangqun; Liu, Jiumin; Zhang, Xu; Xu, Hua.
Afiliação
  • Li H; Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology of Hubei Province, Wuhan, China.
  • Zhang Y; Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Li D; Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Ma X; Department of Urology, Chinese PLA General Hospital, Beijing, China.
  • Xu K; Department of Urology, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
  • Ding B; Department of Urology, the First Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Li H; Department of Urology, Chinese PLA General Hospital, Beijing, China.
  • Wang Z; Department of Urology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Ouyang W; Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology of Hubei Province, Wuhan, China.
  • Long G; Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology of Hubei Province, Wuhan, China.
  • Zeng J; Department of Urology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Liu H; Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology of Hubei Province, Wuhan, China.
  • Yan L; Department of Urology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Zhang Y; Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology of Hubei Province, Wuhan, China.
  • Liu Z; Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology of Hubei Province, Wuhan, China.
  • Guan W; Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology of Hubei Province, Wuhan, China.
  • Hu Z; Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology of Hubei Province, Wuhan, China.
  • Liu C; Department of Pathology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wan J; Department of Pathology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang G; Department of Pathology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Pu X; Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Zhang M; Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Guo L; Department of Pathology, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
  • An R; Department of Urology, the First Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Qi J; Department of Pathology, the First Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Guo A; Department of Pathology, Chinese PLA General Hospital, Beijing, China.
  • Ye Z; Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology of Hubei Province, Wuhan, China.
  • Liu J; Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Zhang X; Department of Urology, Chinese PLA General Hospital, Beijing, China.
  • Xu H; Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology of Hubei Province, Wuhan, China. Electronic address: xuhuawhu@163.com.
Eur Urol ; 79(6): 879-886, 2021 06.
Article em En | MEDLINE | ID: mdl-33579577
BACKGROUND: Whether AR-V7 expression can predict the response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) remains to be explored. OBJECTIVE: To evaluate the predictive value of AR-V7 expression in the prognosis of mHSPC patients receiving ADT. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter prospective cohort study, 310 mHSPC patients commencing ADT were enrolled. Standard immunohistochemical staining was used to assess AR-V7 protein expression in biopsy tissues collected before initiation of ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier survival estimates and Cox regression analyses were used to evaluate associations of AR-V7 status (positive vs negative) with progression-free survival (PFS) and overall survival (OS). RESULTS AND LIMITATIONS: Sixty-four (21%) patients were AR-V7-positive and 246 (79%) patients were AR-V7-negative. The median follow-up for patients not confirmed dead was 25 mo (interquartile range 10-30). Compared to AR-V7-negative patients, AR-V7-positive patients had significantly shorter PFS (hazard ratio [HR] 47.39, 95% confidence interval [CI] 25.83-86.94) and OS (HR 3.57, 95% CI 1.46-8.72). In multivariable analysis, AR-V7 was an independent predictive factor (HR 7.61, 95% CI 5.24-11.06) for shorter PFS. Limitations include the sample size and follow-up period. CONCLUSIONS: AR-V7 expression in primary cancer tissue is correlated with poor prognosis for mHSPC patients receiving ADT. PATIENT SUMMARY: In this study of men with metastatic hormone-sensitive prostate cancer, AR-V7 protein expression in primary cancer tissue was associated with poor outcomes on androgen deprivation therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Androgênicos / Neoplasias de Próstata Resistentes à Castração Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Androgênicos / Neoplasias de Próstata Resistentes à Castração Idioma: En Ano de publicação: 2021 Tipo de documento: Article